Abstract
We have experienced 4 cases of therapy-related leukemia (TRL) in 119 patients with multiple myeloma (MM) who had received combination chemotherapy including alkylating agents between 1988 and 1998. All 4 cases were acute myelogenous leukemia, 3 were males and 1 was female. Median age at diagnosis of MM was 60 years, and median time to TRL from diagnosis of MM was 5.5 years. The chromosome abnormalities were found in 3 of those cases. All 4 cases were resistant to antileukemic chemotherapy, and median survival time from TRL was only 5.5 months. The TRL in MM is thought to be a more important problem, because recently the treatment for this disease has become more intensive, including high-dose chemotherapy supported by autologous stem cell transplantation.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Chromosome Aberrations
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Drug Administration Schedule
-
Female
-
Humans
-
Leukemia, Myeloid, Acute / chemically induced*
-
Male
-
Melphalan / administration & dosage
-
Melphalan / adverse effects
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / genetics
-
Neoplasms, Second Primary / etiology*
-
Nitrosourea Compounds / administration & dosage
-
Nitrosourea Compounds / adverse effects
-
Prednisolone / administration & dosage
-
Prednisolone / adverse effects
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Nitrosourea Compounds
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisolone
-
Melphalan
-
ranimustine
-
Prednisone
Supplementary concepts
-
CHOP protocol
-
VMCP protocol